213 related articles for article (PubMed ID: 31262976)
1. Progesterone receptor antagonist provides palliative effects for uterine leiomyoma through a Bcl-2/Beclin1-dependent mechanism.
Zhang L; Feng Q; Wang Z; Liu P; Cui S
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31262976
[TBL] [Abstract][Full Text] [Related]
2. Effects of progesterone receptor on proliferation of uterine leiomyoma cells.
Liao S; Mi HN; Chai LY; Wang HN
J Biol Regul Homeost Agents; 2019; 33(6):1685-1693. PubMed ID: 31696694
[TBL] [Abstract][Full Text] [Related]
3. Ovarian steroid hormones modulate the expression of progesterone receptors and histone acetylation patterns in uterine leiomyoma cells.
Sant'Anna GDS; Brum IS; Branchini G; Pizzolato LS; Capp E; Corleta HVE
Gynecol Endocrinol; 2017 Aug; 33(8):629-633. PubMed ID: 28300476
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.
Baytur YB; Ozbilgin K; Cilaker S; Lacin S; Kurtul O; Oruc S; Koyuncu FM
Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):94-103. PubMed ID: 16973256
[TBL] [Abstract][Full Text] [Related]
5. Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells.
Luo X; Yin P; Reierstad S; Ishikawa H; Lin Z; Pavone ME; Zhao H; Marsh EE; Bulun SE
J Clin Endocrinol Metab; 2009 Nov; 94(11):4533-9. PubMed ID: 19808856
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide progesterone receptor binding: cell type-specific and shared mechanisms in T47D breast cancer cells and primary leiomyoma cells.
Yin P; Roqueiro D; Huang L; Owen JK; Xie A; Navarro A; Monsivais D; Coon JS; Kim JJ; Dai Y; Bulun SE
PLoS One; 2012; 7(1):e29021. PubMed ID: 22272226
[TBL] [Abstract][Full Text] [Related]
7. Progesterone Receptor Isoforms, Nuclear Corepressor-1 and Steroid Receptor Coactivator-1 and B-Cell Lymphoma 2 and Akt and Akt Phosphorylation Status in Uterine Myomas after Ulipristal Acetate Treatment: A Systematic Immunohistochemical Evaluation.
Courtoy GE; Donnez J; Marbaix E; Barreira M; Luyckx M; Dolmans MM
Gynecol Obstet Invest; 2018; 83(5):443-454. PubMed ID: 29227976
[TBL] [Abstract][Full Text] [Related]
8. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS
J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797
[TBL] [Abstract][Full Text] [Related]
9. Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells.
Yin P; Lin Z; Reierstad S; Wu J; Ishikawa H; Marsh EE; Innes J; Cheng Y; Pearson K; Coon JS; Kim JJ; Chakravarti D; Bulun SE
Cancer Res; 2010 Feb; 70(4):1722-30. PubMed ID: 20124487
[TBL] [Abstract][Full Text] [Related]
10. Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells.
Yin P; Lin Z; Cheng YH; Marsh EE; Utsunomiya H; Ishikawa H; Xue Q; Reierstad S; Innes J; Thung S; Kim JJ; Xu E; Bulun SE
J Clin Endocrinol Metab; 2007 Nov; 92(11):4459-66. PubMed ID: 17785366
[TBL] [Abstract][Full Text] [Related]
11. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth.
Yoshida S; Ohara N; Xu Q; Chen W; Wang J; Nakabayashi K; Sasaki H; Morikawa A; Maruo T
Semin Reprod Med; 2010 May; 28(3):260-73. PubMed ID: 20414849
[TBL] [Abstract][Full Text] [Related]
12. [The molecular mechanisms and morphological manifestations of leiomyoma reduction induced by selective progesterone receptor modulators].
Demura TA; Revazova ZV; Kogan EA; Adamyan LV
Arkh Patol; 2017; 79(3):19-26. PubMed ID: 28631712
[TBL] [Abstract][Full Text] [Related]
13. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
[TBL] [Abstract][Full Text] [Related]
14. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas.
Vu K; Greenspan DL; Wu TC; Zacur HA; Kurman RJ
Hum Pathol; 1998 Apr; 29(4):359-63. PubMed ID: 9563785
[TBL] [Abstract][Full Text] [Related]
15. Hormones and pathogenesis of uterine fibroids.
Reis FM; Bloise E; Ortiga-Carvalho TM
Best Pract Res Clin Obstet Gynaecol; 2016 Jul; 34():13-24. PubMed ID: 26725037
[TBL] [Abstract][Full Text] [Related]
16. [Effects of mifepristone on estrogen and progestin receptors in human uterine leiomyoma].
Wang H; Jin J
Zhonghua Fu Chan Ke Za Zhi; 2000 Feb; 35(2):79-81. PubMed ID: 11809103
[TBL] [Abstract][Full Text] [Related]
17. A-Kinase Anchoring Protein 13 (AKAP13) Augments Progesterone Signaling in Uterine Fibroid Cells.
Ng SSM; Jorge S; Malik M; Britten J; Su SC; Armstrong CR; Brennan JT; Chang S; Baig KM; Driggers PH; Segars JH
J Clin Endocrinol Metab; 2019 Mar; 104(3):970-980. PubMed ID: 30239831
[TBL] [Abstract][Full Text] [Related]
18. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells.
Chen W; Ohara N; Wang J; Xu Q; Liu J; Morikawa A; Sasaki H; Yoshida S; Demanno DA; Chwalisz K; Maruo T
J Clin Endocrinol Metab; 2006 Apr; 91(4):1296-304. PubMed ID: 16464945
[TBL] [Abstract][Full Text] [Related]
19. Expression of Concern: Progesterone receptor antagonist provides palliative effects for uterine leiomyoma through a Bcl-2/Beclin1-dependent mechanism.
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33821978
[No Abstract] [Full Text] [Related]
20. Autophagy up-regulation by ulipristal acetate as a novel target mechanism in the treatment of uterine leiomyoma: an in vitro study.
Del Bello B; Marcolongo P; Ciarmela P; Sorbi F; Petraglia F; Luisi S; Maellaro E
Fertil Steril; 2019 Dec; 112(6):1150-1159. PubMed ID: 31843092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
